All three of the pharmaceutical drugs unveiled today have the ability to reduce blood sugar level. All three have anti-histamine properties.
The three drugs were unveiled at a special ceremony on Tuesday morning, attended by the Iranian health minister, Hassan Ghazizadeh Hashemi.
The first drug to be unveiled was "Neothadine", a new second-generation anti-histamine drug, approved by the FDA. It has a triple-ring molecular structure, and is produced in the form of a five milligram tablet / capsule, as well as in liquid (suspension) form.
The drug imparts its effect less than an hour after being swallowed, and has maximum effect about three hours after consumption. Its effect lingers on up to 24 hours after consumption.
The second drug to be unveiled was "Gloripa", a drug which is eaten or swallowed and has the effect of reducing blood sugar level.
The drug is classified as an SGLT2 inhibitor, and has been approved by the FDA. This is the first time that such a drug is manufactured inside Iran. The drug has been proven to reduce significantly mortality associated with pulmonary heart disease.
Studies also show that the drug halts the advancement of kidney disease associated with diabetes, and it also lowers blood pressure.
"Gloripa" should be taken just once every 24 hours , and 10 milligram and 25 milligram capsules are available.
The third pharmaceutical drug to be unveiled was "Sinoripa", another powerful combination drug that reduces blood sugar level.
Sinoripa is available in tablets / capsules and is in effect two drugs -- both of which reduce blood sugar level -- rolled into one.
